## Antoine E Azar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7555547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. International Forum of Allergy and Rhinology, 2018, 8, 108-352.	1.5	273

## 2 囼2é™...èᇿ•ë,Žé¼»ç§ʻå¦å...±è⁻†å£°æ˜Ž : å•应性é¼»ç,Ž. International Forum of Allergy and Rhinology, 2018, &5108-35224

3	Screening for Beta-Lactam Allergy in Joint Arthroplasty Patients to Improve Surgical Prophylaxis Practice. Journal of Arthroplasty, 2017, 32, S101-S108.	1.5	57
4	Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: AÂWork Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology, 2022, 149, 1525-1560.	1.5	53
5	Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized doubleâ€blind placeboâ€controlled trial. Clinical and Experimental Allergy, 2021, 51, 836-844.	1.4	51
6	Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2017, 12, e0172437.	1.1	45
7	Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1434-1453.e9.	2.0	35
8	Evaluation of the Adult with Suspected Immunodeficiency. American Journal of Medicine, 2007, 120, 764-768.	0.6	32
9	Considerations in the Diagnosis of Chronic Granulomatous Disease. Journal of the Pediatric Infectious Diseases Society, 2018, 7, S6-S11.	0.6	29
10	Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS ONE, 2018, 13, e0194924.	1.1	25
11	Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response―by Bonelli <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e164-e164.	0.5	17
12	Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review. International Forum of Allergy and Rhinology, 2018, 8, 982-992.	1.5	13
13	Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis. Kidney International, 2022, 101, 414-415.	2.6	13
14	Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course. , 2022, 9, 93-99.		6
15	Systemic Lupus Erythematosus and Common Variable Immunodeficiency. Journal of Clinical Rheumatology, 2022, 28, e245-e248.	0.5	3
16	Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation. Case Reports in Immunology, 2019, 2019, 1-4.	0.2	2
17	Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment. Blood, 2021, 138, 4310-4310.	0.6	2
18	Hypogammaglobulinemia with normal antibody response progressing to common variable immunodeficiency. Annals of Allergy, Asthma and Immunology, 2015, 114, 522-523.	0.5	1

#	Article	IF	CITATIONS
19	EBV-positive B-cell Ulcerative Proliferation in the Oral Cavity Associated with EBV-negative Follicular Lymphoma in a Patient with Common Variable Immunodeficiency: A Case Report and Review of the Literature. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, , .	0.2	1
20	Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis. Cureus, 2019, 11, e6367.	0.2	1